Coronavirus Update: No Mortality Gains From Remdesivir In WHO Trial, Gilead Questions Results

Trial Involved 11,000 Patients

Plus Sanofi and Translate Bio release preclinical data from their COVID-19 vaccine candidate, another entrant to the now crowded mRNA vaccine field.  

WHO
The SOLIDARITY trial results have been praised by academic researcher leaders, but questioned by Gilead.

A large-scale open-label trial of re-purposed drug treatments for COVID-19 involving over 11,000 patients has found none of them – including Gilead’s remdesivir – helped improve patients’ chances of survival.

The World Health Organization’s SOLIDARITY trial was conducted in 405 hospitals in 30 countries and examined the effects of remdesivir,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip